REGISTERED NUMBER.. 07251522
CHARITY NUMBER.. 1139367
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
(A company Ilmlted by guarantee)
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Page
Reference and admln15tfatlve Informatlon
Trustees, Report
Independent Audltor's Report
8-10
Stat8m8nt ol flnanclal actlvltles
Balance Shfrot
12
Notes to the Flnanclal Statements
13-21

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2026
REFERENCE AND ADMINISTRATIVE INFORMATION
Charlty number..
1139367
Company numb•T.'
07251522
Regl$lered Ofll¢g'.
16 Great Queen Street
Covenl G8rden
London
WC2B 5DG
Prlnclpal Offlco..
Medical microblol￿Y
Aberdeen Royal Infirtnary
Ab&rdeen AB25 2ZN
Scotland, UK
Trustees:
Professor Geoffrey Coomb5
Professor Souh8 K8nj
Professor Heiman Weriheim
Professor Anuradh8 Chowdhaty
Or David Jenkins
Perth, Australla
Beirul, Lebanon
Nijmegen, Neth8rtand5
Loughborough, England
Chlel
Ollicer
Executlv& Dr Fiona Ma¢Kenzle
Audltor
Atels Audit SeNices
Chartered Accountants
5th Floor, 16 Gr8al Queen Streel
Covenl Garden
London
WC2B 5DG
Investment Manager
Ralhbon& Inv85tmenl Manager Limiled
8 Fin5bury Circus
London
EC2M 7AZ
8ank8r
Th8 Royal Bank of Scotland
Aberdeen Business C8nire
Aberdeen Queen'5 C1059 Branch
40 Abyn Place
Aberdeen
AB10 1YN
Sollcltor
Ledingham Chalmer$ LLP, Solldtors
Johnston8 Hous8
52-54 Rose st￿et
Aberdeen
ABIO 1HA
Page 1

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
The Trustees present their annusl report and financi815t818rnents of thg Charity for the year ended 31 December
2025. The finanaal statements have been prepared in accordance wilh the accounting policies sel out in nole 2 10
the 8ccounls and comply ￿rith the Charities Act 2011, Companies Act 2006 and the Statement ol Recommended
Pr8¢11￿. Accounting and Reportino by Charities applicable to charities IFRS 102118ffecliv8 January 20151.
OBJECTIVES AND ACTIVITIES
To advance th8 education 8nd the Scien￿ of therapy ol infection through Ihe eslablishmenl ol an inleinalional
federation of affilial8d national and r￿IOnal societies with similar aims and objectives to those ol the Charity. In
meebng the objectives, the charitable company shall..
81 Piorno18 th8 conduct of s￿ents￿¢ re8e8rch, convening international coryresses, C￿nIeren￿$ and symposia.
bl Encourage Ihe co-operation of the members of the Charity Ilhe °Members'l 8mongsl th8mselv88 and
bettveen scientists belonging lo societies dealin9 wilh r81ated b8sic and clinical sci8nc88
cl Encourage the formation ol nakn'onal and regional societies interested in therapy of infeclion in those countries
or areas where such groups do not othetwse exist.
dl Encourage andlor sponsor the formation ol international working groups lor special research. trainino
projects or the use ol therapeutics in the field of Enti-inf8cb"v8 Ih8rapy anis co-ordinating their a¢tiMties.
el Produce, publish 8nd distribute Iwh81hef graluilously or noll or to make 9fanls towards Ihe costs ol others
produring. publishing ordislribuling material in any form including journals, books, pamphlets, feports, films,
takes, progiammes or web-based maleiial that rn8y b8 de8med desirable for th8 furih8r8nce or promotion
ol the Objects or lor the purpose of informing contributors and others of the need or piogress ol the Charity
Aw8rd scholarships and bursaries r8ised from third party contribution5 to enable attendance at 8nd travel to
any inlern8lional congfesses organised by the Chanty by pe150ns desetwng of such assis18nce as
shall be decided at the discretion of th& Dir8clors and ExeGutsve Committee.
The pollcle8 that have been adopted In order that the oblectlv69 arè mot ar•..
al The biennial Inlernalional Congiess ofAntimicrobial Ch8motherapy IICCI is held in major cities throughout
the world. According lo the ICC schedule, the nexu34￿ ICC will be held in Manila, Philippines Ifom 7 to 9
De￿rntser 2026.
bl The Executs"ve Commilleè holds quartedy m881ings to appraise the activities of ISAC and lo receive reports
Irorn Ihe Tru51ees.
cl Working groups may be lomed to 8ddtys5 curf8nl Issu88 with reg8rd lo anlimicrobial ¢hemolherapy
dl The highe81 ISAC Award (the Harnao Umezawa Memorial Award) given at every ICC is donated by the
Microbial Chemistry Research Foundalion, Japan. There is an oulrighl grant ol a sum ol money, together
with a ￿rtifiCate and me<Sal lo the reapienl.
The Charity has established 'Young Invesligalors Travel Awards. to be given at every ICC lo desemng
participanls presenting original work to allend the ICC.
The'Torn B8rgan Mernorial Fund, w83 eslablished in July 20013nd Ihe'John David Wlliams Memorial Fund.
was established in 2UU5. Ihese Funds each provide two travel grants enabling deserving young
invesli981ors presenting original work to allend the ICC.
el Publicalion5'. Th8 Charity publishes th8 Intemational Journal of Antimicrobial Agents IIJAAI12 volumes with
12 issues peryearl and the Journal ol Global Anlimicrobial Resistan￿ IJGARI which is published quarterly.
ISAC 8ssisls Member Societies in National and Regional Meeting8.
gl Mernbgrship.. ISAC has 107 affiliated Member-societies. There are no membership lees.
h) Finances.. Hisloncally, thew havo been two main revenug streams ol the Charity. The first is the surplus I
souety sh8ie in the oiganisation of th8 biennial ICCS. The profils from ICCS are generally shared with the
loc81 M8mb8r-Society liesl. In recent years however, including 2024, the ICC has made a loss and has cost
ISAC rnoney. The second source ol income is royalty payments from Ils joumals,. IJAA and JGAR.
The Cha￿ty h8s appoin18d an Investment Manager who advises and generates revenue from the Charity's assets.
Th8 revenue obtained shall be used in the yearly expenditure ol the Charty.
Pag8 2

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
ACHIEVEMENTS AND PERFORMANCE
Developments and actlvltles for the year 2025
al The ISAC Officers and Execulive Committee rnembers during 2025 are detsiled below..
Pr@sld8nt
S. Kanj ILebanonl
2024- 2028
Pr851dent-EleGt
H. Werlheitn INeth&rlands1
2024- 2026
Secr8tary-Gen8r81
A Chowdhary Ilndial
2024- 2028
Hon Treasurer
D. Jenkins IUKI
2024- 2028
Immedlate Past Pr@sldenl
G. Coombs IAu$lralial
2024- 2026
Ordlnary members
R. Betba (Philippi￿$}
M Dav￿ IUSAI
M. F8lcon81118lyl
P. Munoz (Spain)
K. Yanagihara (Japan)
2022- 2026
2024- 2038
2024- 2028
2022- 2026
2024- 2028
Ex-offlclo members
IJM Editor in Chief
JGAR EdiloT in Chief
Chlef Exe¢ubve 0￿￿er
2024- 2026
2024- 2028
APSCMI repre5enlalive
Young invesb'galor representative
A. Tsaklls (Greecel
F. Ma¢Kenzie IUKI
J. Munila (Chilel
S. Essack (South Afric81
O. Lye (Singapore)
J. Zhao (Auslralial
bl Trustee fa￿-tO-faCe meetings took place in London in February 2025 and Auslria in April 2025. Month
meèbngs held via Microsoft Teams also took placè.
cl ISAC conb.nued ils online webinar proJfamme. The following We￿ held in 2025..
8acleriophage Iher8py.' where are we now?
Artifiaal intelligence in Anti-lnleclives
D8rwin m88ls the £ntibiotic crisis
Anlimicrobial stewardship in critica1 care units
Emerging and re*merging inleclions among migrants
Innovations and challenges in HIV prgvention and cur8
Managing MDR infections in the ICU.. anlibiolics, therapy duralion and immune modulation
Oplimising Anb"microbi81 Th8r8py in Cnlical Care. From Levels lo Outcomes
WHO fungal priority pathogens list. challenges in diagnosis and rnaTrag8m8nt
Establishing the Role ol Inleclious Diseases & Clinical Microbiology Societies
Page 3

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
ACHIEVEMENTS AND PERFORMANCE-contlnued
dl Publlcatlon8'.
InteTnatlonal Journal of Antimicroblal Agents
The edilon81 orrice is situated in Elsewer's offices in Oxford, UK. All aspecls of joum81 praduchon are handled
Vl8 the electronic Elsevier Editorial System IEESI. The number ol submissions to the journal continue5 to
increase significantly as has the workload ol the Elyitor in Chief.
A contract was enler8d into b&￿88￿ ISAC and EI88M8r is eff8cliv8 from 1 January 2020 to 31 Dec￿Trb8r 2024.
It automatically renewed lor three years until 31 December 2027. Elsevier have a direct conliacl wilh the IJAA
Edilor-in-chiel, currently Profèssor Jan Li IAuslralial and pay him direct. His current contract runs from
1 January 2025 to 31 December 2027.
In 2025, the Impact Factor for IJAA increased from 4.6 to 5.0. IJM is now ranked in the following posilions in
the Journal Citalion Reports..
Inf8clious Di8e8ges 23 1141 journals
Microbi01ogy 47 1167 journals.
Pharmacology & Pharmacy 701356 joumals.
IJAA Is sn online only journal.
Journal of Global Antlml¢roblal Reslstance IJGARI
In 2013 ISAC launched a seconcs journal,. the Journal ol Global Anlimicrotiial Resistance IJGARI. The lille is
100U/o owned by ISAC which enlefed Into an initial five-year publishing agr&ernenl wilh Elseviei Ltd. The Initial
contiacl expired in De1￿mber 2019 and automatically rolled over for a further Ihree-year period until December
2020. ISAC and Elsevier renewed the conlracl early. effe¢live from 1 January 2020 10 31 December 2022. It
automatically iollecl over and now expires on 31 December 2028. ISAC has a direct conlfacl with the JGAR
Edilor-in-chief, currently Professor Alhanasios Tsakiis IAlhens. Greece) and pay5 him direct. H15 conlfacl tuns
from 1 October 2024 to 31 December 2026.
In 2023 the Impact Factor increased Ifom 3.2 to 3.7 and il is now ranked in the following positions in the Journal
Citation ReportS'.
Infectious Diseases.. 44 1141 journals.
Pharmacology & Pharmacy.. 120 1356 journals
FINANCIAL REVIEW
Overall income lor the charity was £360,070 l£nil restricted income) in 2025, compared to £335,087 l£nil restricted
income) in 2024. The increase in unreslricted income is mainly due to Inc￿aSer1 journal royalty income.
The charity exp8ns8s for th8 y88r w8re £275,355 lof which £nil was reslrict8dl. comp8r8d lo £329,905 lof whieh
£9,393 was restri¢ledl in 2024.
R8serv88
The applicalion ol the Charity's funds lor 2025 is as presented in the accompanying audited accounts. The balan
at 31 DeTrmber 2025 is £5.944,83712024. £5,260,442).
Al the 31 Decemb8r 2025 th8 charity had 3 designaled funds lolalling £40.71812024. 5 101811ing £115,396) and 1
reslri¢led fund tolalling £1(b,76812024.' £106,768). See note 16 to the finanaal statements lor more dètails.
R8serves Pollcy
The policy ol the Trustees is lo maintain reserves at a minimum level of £1,000.000. This provides sufficient funds
to cover operalional costs and respond to emergency costs. Planning lor the bi-annual Conofesses OCCUfS several
months in advanc8 This means co8ls are incurred well before th8 congr85s lak8s plac8 8nd non-atlendance due
to exceptional circums18ncAs c8nnol b8 piedi¢led. Th8 Charity aims lo keep suffia8nt in reserv8 to cover 8ny
unlofeseen congress costs.
Page 4

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2026
FINANCIAL REVIEW- continued
Investment Polley
The objective has been lo provide capita1 growth and also to generate income for charitable purposes. The
achievement ol the policy 15 nionilored through discussions with th8 investfflent manag8rs and me85uiemenls
against appropriate benchmarts. The Trustees are sabsfted with the ad￿￿ given on slfalegy and minimising risk.
ISAC'S 8thie£l ￿nveStrnenI policy $peryficAlly exdudes companies known lo be dealing in tobacco, arms, alcohol and
gambling and also excludes pharmaceutical companies due to the conflict ol inlefesls. The policy ol the Trustees
is lo maintain the investment balan￿ at a minimum level of £3,500,000.
Investment Perfomiance
Thè inv85tsn8nt portfolio at 31 De(￿￿bar 2025 had a total a5S8t valu8 of £5.120,379 compar8d lo £4,490,879 in
2024.
Fixed Interest
Equity
18.72
UK
North Affl8rica
Japan
Europe
Asi8 Pa¢ific
Emerging Markets
Global Inveslmenls
Actively Managed Slr818gies
Commtsjities
Cash
Total
24.10
28.13
4.03
5.99
251
1.68
6.67
2.28
3.46
2.43
100.00
Risk Managemen¢
The major risks lo which the charitable company is exposed, as identified by the Trustees are under a continual
prO￿$S ol review and procedures ar6 In place to managè thosè risks. Piole5sional indemnity insuranc6 is piowded
for the org8nisalion.
FUTURE PLANS
During 2025, ISAC continued lo progress engagement with ils Executive Committee members lo deliver the soaety
strategy in an inclusive I transparent way. ISAC undertook a"slrategy rewe￿ in Septembei 2025 In Athen5. As a
COn58quence of that meeting. ISAC is currently recruiling an additional member of stsff to join the ISAC office, lo
progress strategic priorities idenlified al the meelirvJ.
In 2024. ISAC delivered ten live webinars as part oflhe online'lSAC Acadernf and plans tO￿ntinue Ihis successfvl
ISAC is partnering with one of ils Member Socielies, the Philippine Society for Microbiology and Inleclious Diseases,
lo deliver the 34￿ Icc in in Manila in oe￿mber 2026. Having soliated bids. ISAC is currently looking lo identify a
suitable Memb8r Society lo co-host the ICC in 2028.
ISAC made available a number ol proiect grants and souety grants in 2025 and plans to continue this initiate.
ISAC continues lo develop the ISAC Anlibiolic Tre8lm8nl Guidelines.. an open acrsss onlin8 antirri¢robi81 trealment
guideline. 11 was launched in September 2024 in collaborglion with Radboud university medical cenlre
(Radboudumel, thè Netherlands and the Amèrican UnN6rsity of Beirut Medical C6ntr6 IAUBMCI 8nd will Ir8nsition
rully ov81 lo ISAC by 1 January 2028
Page 5

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
STRUCTURE, GOVERNANCE AND MANAGEMENT
The Inteination81 Society of Antimicfobi81 Chemolher8py (previously The International Society for Infection and
C8ncerl IISACI is 8 company limited by guarantee incorpofated on 12 May 2010 and registered wth the Chanty
Commission on 20 December 2010. ISAC operates under the tules s81 out in Artic18s Association, which w8re
updated on 2 Oclober 2017. The Ch8rity has £ssociated Member Societies throughout the world. The Trustees
are the sa￿ety Pr8sid8nl, Piesidenl-Elecl, Immediate Past President, Secrelary-General and Honorary Treasurer.
Publlc benellt
The Trustees have considered the Charities Comrnission's requirement in ￿SpeCt ol Public Benefit. In their view
the Charity meets. in full, the criteria lo satisfy the lest. The Trustees, have d85CFibed earfi8r in this report Ihe
aclivibes undertaken to further Ils chsnlable purposes foi the public b8nefit.
Tru8tees
The Executive Offi￿r$ ol the Society work volunlariSy for the Charity. They 8r8 g8n8r8lly p£id employ888 of
univ8rsilies or hospitsls in their own covnlry or are reliied lfom paid employment and have limited resour￿$ and
lirni18d lirne for the Charity. The Charily supports these Officers In terms ol help In funding trave￿ in connection with
the Charity's work and in line with Ihe Chanty'5 financial guideline5 le.g. Me8ling8 on progr88s of congr8SS85, on
Publications, arF(I with Investment Adw5er5 and Bankers).
Pagè 6

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
STATEMENT OF TRUSTEES. RESPONSIBILITES
The trustees (who are also directors of The InteiTralional Society ol Antimicrobial Chemolherapy for the purposes
of company lawl ale ie5ponsible lor preparing the Trustees. Annual Report anrl the financi31 statements in
accordance wilh applicable law and Uni18d Kingdom Accounting Standards Iuniled Kingdom Generally Accepted
Accounting Piaclicel.
Company law requires the Ituslees lo prèpare financi81 statements lor each finan￿al year, which give a tru9 8fKI
[811 wèw of the slate olaffaiis ol the charitable company and of the incoming r850uice5 and applical'on ol resources,
including th8 income and expenditu￿, ol the charilable company for that period. In preparing these finanoal
slalemenls, the trustees are reouir8d to..
select suitable accounting policies ancl then apply th8rn COnS15tenlly,
observe the methcds and principles in the Charities SORP 2015 IFRS 1021..
mak8 judgements and ests"mates that are reasonable and prudent..
stale whether applicable UK Accounl'ng Standard8 have been followad. subject lo any material
departures disdos&d and explained In the financial stalemenls.,
prepare the f nancial statements on the going con￿rn basis unless it is inappropriate to presum8 that
the charitable company will continue in operation.
The trustees are responsible for ke8ping adequ81è accounting records that disclose with reasonab18 accuracy at
any tim& lh8 fin8ncial posits.on ol the charitable company and enable Ih8m to ensure Ihat the financial statements
comply wlh the Companies Act 2006. They Bre also responsible lor safeguarding the assets ol the charitable
company and hence lor taking re8sonab18 Steps for the prevention and detection ol fraud and other irregul8riti&s.
In so f8r a5 the Iru51eès arè aware..
there is no relevant audit information of which the charitable company's auditor is unaware,. and
U)e trustees have taken all steps th81 they owht to h8V6 taken lo make themselves aware ol any relev8nt
audit informalion and to establish that the auditor is awar8 of that inlomiation.
Approved by Ihg Truste85 on 'Lg gq 201
and signed on lh9ir behalf by
Dr David Jenklns
Treasurer, Director and Trustee
Page 7

INDEPENDENT AUDITOR'S REPORTTO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF
ANTIMICROBIAL CHEMOTHERAPY
FOR THE YEAR ENOED 31 DECEMBER 2025
Oplnlon
We have audited Ihe financia1 slalem8nls ol The International Socioty ol Ants"microbi81 Chemolher8py Ilhe
'chanlab18 company'l for the year ended 31 December 2025 which comprise th& Stal8m8nl of Fin8n¢i81 Aclivi118S,
the Balance Sheet and notes lo the financi81 slalem8n18, including a sumrnary ol significant attounting polioes.
The finanoal reporiing Ifamework th81 has b8en applied in their preparation is applicable law ancl United Kingdom
Accounting Standards, including Fin8n¢ia1 Reporting Slarpdard 102 7he Financi31 Reporting Sl8nd8rd 8pplic8b18 Iri
Ihe UK anrl Republic of Irelancl (Uniled Kingdom Generally Accepted Accounting Practic61.
In our opinion the financial 518temerils-.
giv8 a Ifue and fair view ol the slate ol the charitable comp8ny'5 affairs as 8131 D8cember 2025. and of
ils in¢oming resources and appli¢alion ol resources, includin9 ils incom8 and expenditure, lor the year
Ihen ended",
have Leen propady prepared in accordan￿ wilh United Kingdom GenerallyAC￿pted Accounting Pract'ce,"
and
havg been prepared in accordan￿ with the requ1￿MentS of the Companie5 Act 2006.
Basls for oplnlon
We conducted our audtt in accord8nce with Inlernaliona1 Standards on AudilirKJ IUKI IISAS IUKII and 8pplicable
law. Our responsibilities under those standards are further described In the Audilorfs responsibililie8 for Ihe audit of
the finan￿81 slalements section ol our report. We zre independent of the charilable company in accordance with
Ihe ethical requiiemenls Ih818re relevanl lo our audil ol the financial slalemen15 In the UK. including the FRC'S
Elhical Standard. 8nd w8 hav8 fulfilled our other ethica1 iesponsibililies in accordance with these requirern8nls. We
b81i@ve Ih21 the audit eviden￿ we have oblaine(S is suffioenl and appropriate lo provide a basis for our opinion.
Concluslon5 rolatlng to golng concern
In a￿Siting the finan￿81 stslemenls. we have concluded that the Irustees, use of the going conc&rn basis of
accounting in the prepar8lion ol Ihe finanual slatemenls is appropriate.
Based on the work we h8ve pertotm8d, we hav8 not identified any material Un￿rtain￿"es relating lo evenls or
conditions that, individually orcolleclively, may cast significant doubt on the charitable cotnpany's ability to continu8
85 8 going cOn￿rn lor a period ol at least twelve monihs from wh8n th8 financial statements are aulhorised lor
18SU8.
Our respon5ibili118s and th8 responsibilities ol the Iruslees wilh respect to golng concetn 8r8 d8scrib8d in th8
r818vanl se¢lions ol this report.
Other Informatlon
The olhei information cornpllse$ the inlormalion included in the trustees annual report, other than the financial
st8lem8nl8 and our auditor's report the￿on. The Iruslees &re responsib18 for the other information contained within
the annual report. Our opinion on Ihe financi8151alement5 does not cov8r the other inlormalion and, except to the
exlenl olherwise exp1icilly slated in our report, W8 do not express any form ol assuran￿ conclusion Ihereon. Our
responsibility Is lo 188d the other infomialion and, in doing so, consider whether thè olhei information is materially
inconsislent with the financial slalemenls or our knowledg8 obtained in th8 cours8 of the audit or 01he￿iSe appears
lo be materially misslaled. 11 we identity such material inconsistencies or apparent material misslatemenls. we are
reouired to detemine whelhei this giv85 rise lo a m8leri81 misslalemenl in thè financial slalemenls themselves. 11,
based OFI the work we havo perforrned, we con¢lude Ihat there Is a material mi&slalement of this other infotrn21ion,
w& are required to report that fact.
We have nothing lo ￿part in this regard
Oplnlon8 on other matters prescilbad by th& Compan185 Act 2006
In our opinion, based on the work undertaken in th8 eOUIS8 of the 8udil'
the inforrnalion given in the Iruslees. report lincorporaling the directors, report) for Ihe financial year foi
which th8 fin8nci81 slalemenls are prepared is consistent with the financial st8181ll8nts,' and
the directors, report has been prep8red In accordanc8 wth 8pplic8ble ￿gaI requirements.
Page 8

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF
ANTIMICROBIAL CHEMOTHERAPY
FOR THE YEAR ENDED 31 DECEMBER 2025
Matters on which we are required to report by axceptlon
In (he liqht ol the knowledge and understanding of the tharitab18 coTnpany and its Ènvironment obtained in the
course ofthe audit, we have not identified material misslatemenls in the directors, report.
We have nothing to report in respect ol the following matters in relation lo which the Companies Act 2006 requires
us to report to you il, in our opinion..
aclequ8le accounting records have not been kept, orfelurns 2dequ8te lor our8udil have notbeen received
from branches not visiled by us., or
the frnancial statements are not in agreement wilh the accounting records and returns., or
certain disclosures ol directors, remuner81ion specified by law 8re not m8de', or
we have not re￿iVed all the inform8tion and 8xpl8nalions we r8quire for our audit- or
Ihe Iw5tees were not enlilled to prepare the financial statements in accordan￿ with the srnall companies,
regime and take advantage of the 8m811 compani85' exernplions in pieparing the directors, report and from
the ￿QUIreMent to prepare a strategic report.
Responslbllltles of trustee8
As explained more fully in the trustees, responsibilit￿$ statement set out on page 7, Iwsle88 (who 8ra also the
directors ol the charitable ￿MpanY foi the purposes ol company lawl a￿ responsible for the preparation ol th8
financial statements and lor being satisfied that they give a tru8 and fair Nq8W, 8nd for such internal control as the
trustees delefminè is ne￿$sary lo enable the preparation ol financial slalements that ar8 fr88 from material
misslatemenl. whether due to fraud or error.
In preparing the finan￿81 slatemenls. the Ifuslees are responsible lor assessing Ihe charitable company's abiltiy lo
continue 8$ a going concein. disclosing, as applicable, matters related to going con￿rn and using the going concem
basis ol accounting unless Ihe Iruslees eithgl intend to INuidale th8 cha￿tab￿ company or to Cease 0￿ratIOnS. or
hav8 no realistic all8rnatNe bul to do so.
Audltor's re8ponslbllltl85 lor the audlt of the flnanclal statements
Our objectives are lo obtain ieason8bl8 85SUf8nc6 sboul whether the financial slalemenls as a whole are free from
materia1 misstalemenl, whether due lo fraud or error. and lo issue an auditor's report that includes our opinion.
Reasonablè assuran￿ is a high level ol assurance, bul is not a guarantee that an audit conducted in accordance
with ISAS IUKI will always d818cl a rn8lerial misstatement when il exists. Misstalemenls can arise from Ifaud or
error and are consKJered material il, individually or in the 8ggregale. they wuld resso￿ablY b8 8xpecled to influence
th8 econornic d&ci5ions ol users taken on the basis ol these financial slalements.
Irregularits"es, induding Iraud, are instances of non-¢ompliance wilh18WS 8nd regulations. W8 design procedures in
ling with our responsibilities. outlined above, to detect material misslalements in respect of irregularities, includin9
fraud. The specifi¢ pro¢eduf8S for this engagement and Ihe extent to which these are capable ol detecting
irregularits-es, including fraud is detailed below..
Enquiry of m8n8g8ment and those charged with goVernaTr￿ around actLial and potential litsgab'on 8nd
claims as well Bs actual, suspected and all8g8d fr8ud,
Reviewing rninules ol meetings ol those charged with governance.,
Assessing the extent ol Complian￿ with Ihe laws and fegulalions considered lo have a direct material
effect on the finanual statements or th8 op8r8lions of the company through enquiry and inspection..
ReM8wing financial statement disclosures and lesling lo supporting documentation to 8SS8ss compliance
with applic8bl8 laws 8nd regulalions.,
Performing audit woth over the risk of m8nag8mènt bias and over￿de ol controls, including tesling of
journal entries and other adjuslmenls lor appropriateness. evaluating Ihe business r81ionsle of significant
transaclions oulsid8 the nortnal eourse ol business and reviewing accounting estimates lor indicators of
polenlial bias.
8eeause ol the Inherent limitations ol an audit, Ihere is 8 risk th81 w8 will not d81ect all irregularikn'es, includlng those
le8ding lo a mateiial mis51atement in the financial statements or nOn￿MplIan￿ wilh r￿ul8￿On This risk incr8ases
the more that compliance wlh a law or fegu181ion is ￿mOVed from the events and Irangaclions (eflecled in the
financial slatemenls. as we will be less likely lo become awaie of instances of noTr-compIian￿. The risk Is also
gr88lei reg81ding ir￿ularl￿"eS occurnno due to lfaud rather than error, as fraud involves intentional cono88lment,
forgery, collusion, omission or rnisrepr838nlation.
A further description ol our responsibilities is available on the Financial Reporting Coun(￿1,8 website at..
hllps.'Ilww.Ir¢.org.uklOui-WothlAudiUAudil-and-asSuian￿IStandards-and-gU1dan￿1Sland8[dS-and-gUidan¢￿-
lor-auditorslAuditors-responsibijilies-for-audiVDèscriplion￿f-au￿1lors-responSlblliIleS-fOr-audIt.aSpx.
This description fomis part ofour audilof5 report.
Pagè g

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF
ANfiMI¢ROBIAL CHEMOTHERAPY
FOR THE YEAR ENDEO 31 DECEMBER 2026
Use of our ieport
This report is made solely to the chaiilable company's members, 3s a body, in accordan￿ with Chapter 3 01 Part
18 ol the Companie5 Act 2006. Our 8udil work has been undertaken so that we might slate to the charitable
cornpany'5 members Ihose maller8 we are required lo slate lo them in an auditor's report and for no other purpose
To the fu118818xlenl permilled by law, we do not at￿pt or assume responsibility 10 anyone other Ihan the charitable
company and the charitable company's memb8rs as a b¢W, for our audit wotk, lor this report, or for the opinions
we have formed.
kn_LLJ
John Howard (Senior Statutory Auisitorl
For and on beh811 of Az8t8 Audit Ser4ices
Slatulory Auditor. Chartered Accountants
Floor,
16 Great Queen Slr88t
Covenl G8rd8n
London
WC28 5DG
Page 10

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
STA TEMENT OF FINANCIAL ACTIVITIES
IINCORPORATING THE INCOME AND EXPENDITURE ACCOUNTI
FOR THE YEAR ENDED 31 DECEMBER 2025
Not•¥
Unrostrlotod
Fund$
Restrlcted
Fund5
Total
2025
Total
2024
Income from:
Charitable Activities
Investment Income
272.620
87.250
272.820
87,250
253,908
81.159
Total Incomlng re8ourc8
360,070
360,070
335.067
Expendlture on:
Raising Funds
Charitable activities
19,618
255,737
19,618
255,737
18,001
311,W4
Totsl resourc9¥ expendèd
275,3S5
276,355
329,905
Net Incomellexpenditur•l before
Investment galns
84,715
84,716
6,162
other recognl8gd galns
Foreign exchange gainslllossesl
Gain5 on investment assets..
Realised gainslllossesl
Unrealised gainslllossesl
12.099
12,099
110,8961
10
164,427
423,154
164.427
423.154
32.312
352.097
599,680
699.680
373,513
Nat movament In funds before
transfer8
684,395
684,395
378,675
Transfer behveen ￿ndS
Net movémènt In funds for the year
684.396
684,355
378,67S
Reconclllatlon ol funds..
Total fvnd8 brought fotward
16
5,153,674
1[￿,768
5,260.442
4,881,767
Total funds carried forward
16
S,83B,069
106,768
6,944,837
5,260,442
All the above amounts relate to Continuing activitiès.
There were no recognised gains and losses other than those slated abovè.
The notes form part ol thesg finan￿81 5tstemenls.
Page 11

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
BALANCE SHEET
(Company number 072615221
FOR THE YEAR ENOED 31 DECEMBER 2025
31 December
2025
31 Decemb&r
2024
Notes
Flxod as8ot8
Inveslmenls
Tangible fixed assets
10
5.120.379
1,790
4,490,879
1.518
5,122,169
4,492,397
Cv¥ient assets
Debtors
Short term deposits
Cash al bank and in hand
269,874
127,183
495,349
244.718
101,213
S44,￿1
13
892,408
890,892
Credltors.. amounts fallin9 du8wlhin one
year
14
169,7381
1122.8471
Net current assels
822.668
768.045
Not as88l8
15
5,944.837
6,260,442
Uniestrlcted fund
General Funds
Designated Funds
Restricted Funds
16
16
16
5,797.351
40,718
108,768
5,038,278
115,396
106.768
6,944,837
5,260,442
Thg financial slalemenls havè been prep8red in accordan￿ wilh the speci81 provisions for small companies under
Part 15 of the Companies Act 2006.
The financi81 slalemenls were approved by the board of Truslees and aulhorised lor is5U8 on I,?
and signed on Iheif behalf by".
[¢391
Dr David Jenklns
Tiea5uier, Dir8¢1or and Tiuslee
The noles fomi part of Ihese finanaal slalements.
Page 12

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDEO 31 DECEMBER 202S
GENERAL INFORMATION
The International Society of Antimierobial Chemotherapy is a charitable company, limited by guar8nlee,
registered In England and Wales. The company's registered number. the charity's registered number and
the regislered office addres5 can be found on the charity information on page 1. Th& chgrilable company's
prinaple pla￿ ol business Inoled in the charity information on page 11 differs from the registered office.
Th8 n8lure of the charitys operations 3nd prinupal aclNities 8re set out on page 2.
In the event ol the charity being woutKf up the Ilabllity in respect ol the guarantee is limited to £1 per
member of the charity.
ACCOUNTING POLICIES
The prinapal 8¢￿UntIng policies adopted. judgements and key sourrRs of 8stimats.on un￿rtainlY in the
p￿paratIonS ol the financial slal8m8nls are as follow..
lal General Informatlon and basis of preparation
Th8 fin8nc4al slalemenls have been prepared in xceord8nc6 with Accounting and Reportiry by Ch8rilies.'
Slalement of Recommonded Pfattice applicable to charities prep8ring their accounts in accordan￿ with
the Fsnancial Reportin9 Standard 8pplicable In the UK IFRS 1021 issued on 16 July 2015 las updated
through UOale Bulletin published on 2 February 20171. the Financial Reporting Standard applicable in
the United ￿ngdoM IFRS 1021. the Charities Act 2011, the Companies Act 2006 2nd UK Generalty
Accepted PracU'Tr as it applies from 1 January 2017.
The charitable company eonstitutes a public benefit entity 85 defined by FRS 102. The financial slalements
are prepared on a going coll￿rn basis under the hislofical cost convenb'on. modified lo include ￿rtain
lems at fair valu8. The financial statements are prep8red in Slerting which is Ihe functional currency of the
charitable company.
Ibl Golng Concern
The financial slalemenls have be8n prepaied on a going Can￿rn basis as the Trusteès b81ieve that no
mate￿81 uncertaintiès exist. The Trustees have consid8red Ihe lèvel ol funds held and expected 18V8101
income and expenditure foi 12 months from aulhorising these financial s18lem8nls. The budgeted income
and expenditure is sufficient with the level of ieserves lor the charity lo be ablg to conb"nu8 as a going
con¢xrn.
Icl Funds
Unreslricled fvnds - repr8sÈnl funds which can be used in accordance with thè charitable objects al the
discretion ol the Trustees.
Designated funds- these at8 funds sèt 89idè by Ihe Trustees out ol unreslricled general funds lor speufic
purposes or projects.
Reslricled fU￿S- represent funds that can only be used forparticular r85trict6(I purposes within the objec15
of lh8 charity. Reslriclions arise when spe¢if18d by the donor or when Ihe funds arg raised for sp8cIfic
restricted purposes.
Further explanation ol the nature and purpose ol each fund is induded in th8 notès to the financial
slatemenls.
Idl Taxatlon
The charity 1$ 8xèmpt from corporation lax on ils charitable 8Ctiwties.
Page 13

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2026
ACCOUNTING POLICIES - continued
lel Income
All income Is Includ8d in Ihe Statement ol Financial Activi1188 ISOFAI when the charity 15 legally 8nlilled lo
the incorne 8fter 8ny perfom)ance conditions h8ve been rnel, the amount can be measured reliably, and il
is probable that the income will b6 receiv8d.
Donalions and legaci85 are recognised In the fin8ncial slalemenls when the Irusle85 81e convinced that
there is entillemenl lo the income. there 15 cert8inty ol receipt and the atnount in question is Measurable.
Income from tha￿l£ble activities indudes income in relation lo conferences and Jouina1 Royalti8s Income
earned from conf8r8nce8 ￿$ included in the year th8 conference is held. Journal income 18 included in line
with the financial year ol the charity.
Investment income 18 earned through holding assets for investment purposes such as shares. 11 includes
div￿endS and inleresl. Dividends are recogni8ed once the dividend has been declared and nolificalion has
b88n re￿iVed ol the dividend clue. Th8 is normally upon notification by or investment advisor ol the
dividend yield ol the investrnenl portfolio. Interest is included when receivable.
lfj Expenditure
Liabilities are recognised as expenditure as soon as the￿ is a legal or conslruclive obligation committing
the charity to that èxpendilur8 It 1$ piobable that selllement will be required, and the 8mount of the
oba￿atIon can b8 rn88sured reliably.
All expenditure is accounted foi on an accrual basis. All expenses including support costs and goveinance
cosls are allocated or apportioned to the applic8bl8 8xp8ndilure headings.
Cosls of raising funds consist ol inveslrnent management lees for th8 Period.
Costs ol charitable activities consist ol those costs incurred by the charity in delivery of 115 activiti8s and
seMc6s lo fvrther th8 charity's obje¢live5.
Governance costs Include Ih08e in¢uried in the governanc6 of th8 charity and its assets and are primarily
associated with constitutional and slalulory requirements.
Irrecover8ble VAT is charged against the expenditure heading for which it was incurred.
Igl Tanglble flxed assets
Tangib18 fixed assets are slated at cost less acoumulated depreciation.
Depieualion 15 piowded on all tangible fixed assets, at iales c8l¢ulaled lo write off the c05t of each asset
on 8 Straighl-line basis Dv•.r the asset'5 eslim81ed useful lives ès follows-.
Offfj￿ equipment- 10% straight line
Ihl Flxed a55et investments
Investments afe a lom) ol basic fingncial inslrumenls and are Initially recognised al Iheir tiansatlion value
and subsequenuy m888ured al their laif value as atthe balance sheetdale using the closing quoted market
price.
All gains and losses are taken to th8 Statement ol Financial Actiwti88 £s they arise. Realis￿ gains and
losses on investrn8nts are c8l¢ulated as the differenc8 b8tween Ihe sale prO￿ed5 snd opening m8rk81
value Ipufchase date if lalerl. Unrealised gains and Ioss8S are calculated as Ihe diffei8nc8 beiween Ihg
market value al the year end and openin9 market value lor purchase dale 11181811.
The charity d065 not a￿UIre pul Op￿on$, clenvatives 01 olh8r complex financial Instrumènts.
The investment in subsidiaries arè m8asur8d al cost less impaimiènl.
P8ge 14

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
ACCOUNTING POLICIES- continued
111 Debtors
Other debtors ale recognised al the set￿ement arpounl due. Prepayments are valued al th9 amount
prepaid. Accrued income is measured 81 thè amounl due to be re￿1ve￿.
(11 Current asset inve5tmentslShort t&rm deposits
Cuiienl asset investments are short18rm highly liquid investments and are held at fair value. These inclLKle
cash on deposit and cash equivalents with a malufily of less than onè year.
Ikl Cash at bank and In hand
C85h at bank and cash in hand include5 cash and short term highly liquid inveslm8nls with a short matuTrty
of thre8 months or less from the date of 8cquisib.on or opening ol the deposit or similar accounts.
111 Credltors
Creditors are rewnised when the￿ is a present obligation resulting from 8 past event that will prob8bly
result in the Ifansler ol funds lo a third party and the amount due lo settle th8 oblwation can be measured
or eslim81gd rèliably.
Olhsi ¢reditors and accruals are recogniséd at their settlement amount due.
Im) Financial instruments
The ch8rity only has financial 8SS8ts and financial liabilities ol a kind that qualify as basic financial
instruments. Basic financi81 instruments are initi811y recognisèd 81 transaction value and subsequently
measured at their settlement value except lor bank loans which are sub58qU8ntly measufed at amortised
cost using th8 effective interest method.
Inl Forelgn currency
Assets and liabilities in f018ign currencies are translated into sterling at the rates ol exchange ruling £1 the
balance sheet dale. Trans8clions in fO￿Ign currencies are Ifanslaled into slerling 81 the rale ruling on th8
date of th8 transadion. All exchange differences are reneeted in the Statement of Finantral Acts"vities.
lol Judggments and key sources of eslimalion uncertalnly
Accounting estimates and judgements are continually evaluèted and are based on histOriC81 experience
and other factors, including expectations ol future events that are believed lo be ièasonable under the
circumsl8nc85.
The following judgernents 18P8rt from those involving estimalesl have bèen made in the pro￿￿$ 01
applying the abov8 8ccounts.ng policies that hav8 had th8 tnost significant effect on amounts reeognised in
the financ431 slalemenls".
Uselul 8conomle lives of fangible assels
The annual depreciation ch8ige lof tangible assets is sensib've lo changes in the estimated usèful
economic lives and residual values ol the assels. The usefvl economic Iiv8s and residual values are re-
assessed annually. They are amended when necessary lo reflect current estimates, based on
technol(gical advancement, future investm8n15, economic ulilisation and the physical condition ol the
assets. See note 11 lor the cairying amount ol the fixtures and eouiRKnenl and compulef equipment 8nd
nolg12gl loi the useful economic lives lor each dass ol assets.
There are no key assumptions cOn￿rnIng the future and oth8r key sources ol estimation uncertainty at
the reporting date that have a Signifi￿nI fisk ol causing a material adjustment to the ￿[ryIng amounts ol
assets and liabilit18S Within the next fin8nry81 year.
Page 15

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
CHARITABLE ACTIVITIES
Unrestrlcted
Funds
Total
2026
Total
2024
International cong￿$$ of Ch8molher8Py
IJAA and JGAR Joufnal Royallies
Olh&r Journal income
258.561
14,259
258,561
14.259
240,064
13.844
272,820
272,820
253,908
In 2024, all the charitablè aclimty inrx)m8 was allributable lo U)e unrestficled fund,
INVESTMENT INCOME
Unrestrlcted
Funds
Total
2026
Total
2024
Income from fix8d asset inveslmenls
Inl818St on bank and short term dèp051t accounts
86,897
353
86,897
353
80,626
533
87,2SO
87,250
81.159
In 2024. all the investment income was attributable to the unreslrieled fund.
RAISING FUNDS
Unrestilct•d
Funds
Total
2026
Total
2024
Inveslrnenl rnanager lees
19,618
19,618
18.001
In 2024, 811 the irTrv8simenl income was attributable to th8 unr85lThcled fund.
Page 16

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
CHARITABLE ACTIVITIES
Unrestrlcted Restrlcted
Funds
Funds
Total
2026
Total
2024
Expenses ofsociety meetings and publicity
Execulive Offi￿ expenses
Sgcrelarial expen5e8
Journ81 costs
Grants
W8bsite costs
Bank charges and foreign curffjnG
movements
Depreciation
Sundry
APSCMI costs
Project and education81
International Congress ol Antimicfobial
Chemotherapy
Support of non-ISAC congresses
Governance costs
Legal and prof85siona1 Fe85
Str8le9y Rewew
Executive office expenses- insuran
Audit and accountancy lees
Accounting subscriplion
31,571
63,983
43.118
19.331
45,296
2,048
31,571
63,983
43,118
19,331
45.296
2,048
27,954
61,159
42,692
17,016
57.221
2.410
418
330
586
36
3.292
418
330
586
1,036
262
212
120
3,236
3,292
124.6671
3,182
124,6671
3,182
73,663
6,537
15
47,555
5,560
13,752
346
47,555
5,560
13,752
346
4.715
13,656
255,737
265,737
311,904
In 2024, all tho ch8rilablè acliwty costs wèr8 allllbulabl8 to Ihg unr951ricled fund.
NET INCOMING RESOURCES FOR THE YEAR
2026
2024
This is slated after cha(ging'.
Auditors, lees..
Audit fee
other non-audit fees
Prior y&ar lov811 l und8r 8CCtu81
10,2(K>
2,986
912
330
9,600
2,520
1,536
262
Depreciation
TRUSTEES EXPENSES
Durfng the year 5 12024.. 71 Trustees were reimbursed £23,929 12024". £28,248) lor travel and other
ècessary costs incuiied during th8 year in Connection ￿ryth thè work of th8 ch8rrty.
The Trustees recelved no remuneration lor their sem￿$ during this year or thè pr6Mous period.
STAFF COSTS
DuTrng the y88r, ISAC employed 1 p8f8on 12024.. 11. The salary c0518 of £38,438 12024.. £38,012) is
included wthin secretarial exp8n8es.
Th&re wère no employees 68rning abovè £60,0(K) pèr annum during Ihis yèar or Iha prior pèriod.
Included within executive offi￿ expenses are ¢osts 01 £63,451 12024.. £60,627) recharged from NHS
Giampi8n foi the Charity'5 share of the s818ry of the Chief Execulive Office for lim8 Spent working on the
Charity.
In 2025, management lees of £4,68012024'. £4,680) were invol￿d by Aceofd Business Partnerships
relating lo secretarial assistance lo the ISAC CEO.
Page 17

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
10.
FIXED ASSET INVESTMENTS
2026
2024
Quoted inv88tm8nt8
Market valuè at 1 January 2025
Additions
Disposals
Realised investment gainslllos5e51
Unrealisèd Invèstmènt 9ainsll105S881
4,490.879
1,396,644
11,354.7251
164.427
423,154
4,064,213
352.922
1310.6651
32,312
352,097
Market value al 31 December 2025
6.120,379
4,490.879
2026
Market Value
2024
Market Value
C08t
Cost
Fixed Interest
UK Equities
Overseas Equilie5
Allerllaliv8S
945,778
655,118
1.471.728
252,237
982,337
1.207.744
2,571,974
358,324
658.5D9
831,483
1,186,202
438,419
657,458
1,176,057
2,093,070
564,294
3,324,861
5,120,379
3,114,613
4,490,879
In 2025 Ihere were no12024'. £nill inveslmenls in thè yoar that r8pr888nted 5Q/) ofth8 manag8d portfolio
8t the yèar-ènd.
TANGIBLE FIXED ASSETS
Olllce
equlpment
Total
Cost
Al 1 January 2025
Additions
3,770
602
3,770
602
Al 31 Decernbgr 2025
4,372
4,372
D8preclation
Al 1 Janu8ry 2025
Charge
2,252
330
2,252
330
Al 31 D8cember 2025
2,582
2,582
Net book value
At 31 Oecember 2025
1,790
1,790
At 31 December 2024
1,618
1,518
P£g8 18

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 D8cernber2025
12.
DEBTORS AND PREPAYMENTS
2025
2024
Trade debtors
Prepayments and acLrued income
80
269,794
244,718
2S9,874
244,718
13.
SHORT TERM DEPOSITS
2025
2024
Amounts held by sl¢)ckbrokers
127,183
101,213
14.
CREDITORS.. AMOUNTS FALLING DUE WITHIN ONE YEAR
2026
2024
Other creditors and awruals
Tr8de Creditors
69,738
118.317
4,530
69.738
122,847
15.
ANALYSIS OF NET ASSETS BETWEEN FUNDS- curr&nt year
Tanglble flxed
assets and
Inve$lm8nt$
Curr8nt assets
Total
General funds
Designated funds
Restricted fvrKIs
5.722,169
675,182
40.718
106.768
5,797.351
40.718
108.788
6,122,169
822,668
6,944,837
15.1 ANALYSIS OF NET ASSETS BETWEEN FUNDS- prioryear
Tanglblè flxèd
assets and
Investments
Current as$et8
Total
G6n&r81 tunds
Designated funds
Reslricled funds
4,492,397
545,881
115.396
106,768
5,038,278
115.396
10S.768
4.492,397
768,045
6,260,442
Page 19

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
16.
FUNDS
The movement ol fvnds in the current year are as follows..
Inveslm8nl
Forol9n
gxchangB
g41N51
IIos8esl
Balance at
31.12.24
Incomlng
resources
Outgolng
r9s0urces
TranslerB
Balancè at
31.12.25
11055951
Restrlcted funds..
European Congress
ol Chemolheiapy
106,766
106,768
Deslgnated fund8'.
Tom Beigan / JD
Williams
ICC Travel Grant
general fund Iformerty
the Inlefnalional
Co-opeialion Fund)
BSI Working Group
UTI Working Group
14,089
114
14,203
16.925
239
17.164
75,490
8,892
3,900 179.3901
459
9,351
115.398
353
4,359 179,3901
40.718
Unrestrlct8d fund..
General lun
5.038,278
359,717 1275,3551
587,581
7,740
79,390 5,797,351
6,260,442
360,070 1275,35SI
587,S81
12,099
S,944,837
The movement ol funds In lh8 prtor y68r ar6 as follows..
Investment
galnsl
11055fj51
Forelgn
gxchangg
Balanco al
31.12.23
Incomlng
iesourGe5
Ouigolng
resourcfr5
Transfers
8alance ai
81.12.24
Ilossgsl
Restated
Restated
Reststed
Restrlcted funds..
European Congfess
of Chemotherapy
118,161
19,3931
106,768
Deslgnat6d funds:
Tom Bergan
JD Willi8ms
Tom 8eioan l JD
William5
1,821
13.982
11.6?11
114.2081
226
11.7401
15,829
14.089
Co-operalion Fund
BSI Working Group
UTI Working Group
21,143
78,992
9,304
307
14.5251
16,925
75,490
8,892
13,5021
14121
125,042
533
16,2651
13,g141
115,396
Unrastrictad fund..
General ￿nd
4,640,564
334,534 1314.2471
384,409
16.9821
5,038,278
4,881,767
33S,067 1329,9051
384,409 110,8961
5,260,442
Page 20

THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2026
16.
FUNDS Icontlnuedl
Restricted funds
The UK based charity'"Europe8n Congiess of Chemotherapy IECCI. wound up during 2019 and
tr8nsferied its fund5 to ISAC. On receipt of this money ISAC agreed to form a European Wort(ing Group.
Ils primary objectives are..
Continue the activili8S 8nd tneetings of th8 South Eastern Congress of Chemotherapy,
The ofganisation and administration of European Surnmer Schools and assoualed themed
meetings.,
and uenerally, the promotion ol and furth8ianc8 of thg objects ol ECC.
Designated funds
The Tom Bergan Memonal Fund and the John David Williams Memorial Fund were established in 2001
and 2005, respeclively, to provide travel giants lo young investigators presenb.ng original work at the ICC.
During 2024, the two funds were merged lor accounting and reportin9 purpose5. Accordingly, the pnor
year comparakn've figures have been restated lo reflect thg combined fund balance and activities. In
addition. travel awards lo18lling £1.740 awarded in 2024 from the meroed fund were Incor￿ clly charged lo
the General Fund. The 2024 figure5 have therBfoi8 been iesta18d to CQFreclly 8llocale these awaids lo th8
merged fund.
The ICC Trave1 Grant Fund Ilormerly the International C￿peratiOn Fund) prowdes travel grants to young
inveslig81ors presenting original work al the ICC. The fund was originally established through donations
from the Japanese Society of Chemotherapy and Saloshi Omura. During 2024, travel awafds lotalling
£4,525 wefe made from the fund,. however, these awaids weie incoirecuy charged to thè General Fund.
The 2024 figures have therèfore bèèn restsled to COTreclly reff8cl the 811or2lion oflhese awards to the ICC
Travel Grant Fund.
Thè Endocardib"s and Blood8lr8am Infections IBSII Working Grovp Fund was established to support the
8clivilies ofthe Endocarditis and Bloc￿streaM Infe¢tions Working Group, which aimed lo provide education
in the fields olepidemiology, palhogenesis, diagnosis gnd tnanagefflenl of blood51r88m infections Ihiough
conference5, confeience proceedings and coordinated re888rch initiatives. As th8 BSI Working Group no
longei exists, this design8led fund was discontinued during the year. The remaining ￿nd balan￿ was
therefore transferred to unreslricled funds.
The Urinary Tract Inlecbon IUTII Working Group co-ordinates various aspects ol UTI management and
clinic deusion making, on a broad inleinalional base.
17.
RELATED PARTY TRANSACTIONS
Ther8 were no related paty transactions during the perioJ12024.' none).
Page 21